Sort
30,917 grants matching “tumor microenvironment”
Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
$393,090Binfeng Lu · Hackensack University Medical Center · R01 · FY2023 · CA
Capture and Characterization of Highly Metastatic Cancer Cell Clusters in Transit from Lung Cancer Patient Whole Blood Specimens.
$393,048Jeffrey Keith Allen · Tumorgen, Inc. · R43 · FY2021 · CA
Memory T Cells in the Tumor Microenvironment
$393,042Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2012 · CA
Memory T Cells in the Tumor Microenvironment
$393,042Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2015 · CA
Memory T Cells in the Tumor Microenvironment
$393,042Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2011 · CA
Tissue and Molecular Pathology (TMP)
$393,019Thomas James Giordano · University Of Michigan At Ann Arbor · P30 · FY2023 · CA
Aging and Leydig Cell Function
$393,013Barry R Zirkin · Johns Hopkins University · R37 · FY2011 · AG
Computational pathology software for integrative cancer research with three-dimensional digital slides
$392,987Jun Kong · Georgia State University · U01 · FY2019 · CA
Tumor Immune MicroEnvironment Facility (Scientific Core)
$392,937Wiem Lassoued · Division Of Basic Sciences - Nci · ZIC · FY2023 · CA
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors
$392,929Ann Richmond · Vanderbilt University · R01 · FY2020 · CA
Metabolic changes in ovarian cancer cells initiated by metastasis to adipose tiss
$392,850Ernst Lengyel · University Of Chicago · R01 · FY2015 · CA
Immune Regulation of Lung Squamous Metastasis
$392,837Chad V Pecot · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA
Regulation of Pathogenic Plasma Cells in Human SLE
$392,825Ignacio E. Sanz · Emory University · P01 · FY2017 · AI
Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition
$392,820Sukyung Woo · State University Of New York At Buffalo · R01 · FY2023 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$392,779Fumito Ito · University Of Southern California · R01 · FY2025 · CA
New Multi-Drug Resistance Mechanism in Multiple Myeloma
$392,773Shigeki Miyamoto · University Of Wisconsin-Madison · R01 · FY2023 · CA
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
$392,764Prasad S. Adusumilli · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA
The Role of post-translational activation of Myc in pancreatic cancer
$392,748Rosalie C Sears · Oregon Health & Science University · R01 · FY2016 · CA
The Role of post-translational activation of Myc in pancreatic cancer
$392,748Rosalie C Sears · Oregon Health & Science University · R01 · FY2015 · CA
Targeting tumor endothelium for cancer surveillance and immunotherapy
$392,740Sonia Sharma · La Jolla Institute For Immunology · R01 · FY2019 · CA
Tumor Cell Biology Training Program
$392,736Hong Wu · University Of California Los Angeles · T32 · FY2012 · CA
Immune Activating CAR-Modified Antigen Presenting Cells
$392,709Carl Deselm · Washington University · DP5 · FY2019 · OD
Discoidin Domain Receptor Tyrosine Kinase 2 in bladder cancer progression
$392,659Dan Theodorescu · Cedars-Sinai Medical Center · R01 · FY2024 · CA
Rapid Motion-Robust and Easy-to-Use Dynamic Contrast-Enhanced MRI for Liver Perfusion Quantification
$392,645Li Feng · New York University School Of Medicine · R01 · FY2024 · EB
Therapeutic Targeting of Breast Cancer Tumor Initiating Cells
$392,632Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2024 · CA